A Justice Department probe of possible price collusion by generic drug companies could lead to criminal charges by the end of the year, Bloomberg News reported Thursday.

The investigation spans more than a dozen companies, Bloomberg reported, citing people familiar with the matter.

Shares of several generic drug makers declined following the report. Among them were Lannett Co. (LCI), which fell 26% to $17.30, Endo International PLC (ENDP), which was down 18% to $14.85 and Teva Pharmaceutical Industries Ltd. (TEVA), down 12% to $38.02.

Full story at http://www.bloomberg.com/news/articles/2016-11-03/u-s-charges-in-generic-drug-probe-said-to-be-filed-by-year-end

Write to nymonitoring@dowjones.com

(END) Dow Jones Newswires

November 03, 2016 15:53 ET (19:53 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Impax labs (NASDAQ:IPXLE)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Impax labs
Impax labs (NASDAQ:IPXLE)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Impax labs